| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
This prospectus supplement updates and amends certain information in our base prospectus, dated December 5, 2023, as supplement...
BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pu...
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy and maintains $25 price target.
BioCardia®, Inc. (NASDAQ:BCDA) ("BioCardia" or the "Company"), a developer of cellular and cell-derived therape...